Nutritional Management of Pancreatic Cancer



Danielle O'Hagan, Specialist Dietitian, BHSCT











Learning outcome:



Improved knowledge and understanding of the nutritional management of pancreatic cancer including pancreatic exocrine insufficiency (PEI)











Pancreatic Cancer UK new campaign



Faster- should be diagnosed within 21 days of being sent for test and start treatment within 21 days of receiving a diagnosis

Fairer- everyone should get the best support regardless of demographics and chance of survival

Funded- government must provide funding to make changes possible (Pancreatic Cancer UK, 2023)











80% of individuals present with weight loss at diagnosis

Contributing factor is pancreatic exocrine insufficiency

Only 50% of individuals diagnosed with pancreatic cancer had been prescribed PERT

Specialist dietetic support and access to PERT are essential











Question 1:

Do you have any experience with patients who have been diagnosed with pancreatic cancer?

YES

SOME

NONE











Question 2:

How would you rate your understanding of PERT on a scale of 1-10?

1-5

5-10

Nil understanding











Malnutrition in pancreatic cancer

- 70-80% patients with pancreatic cancer are malnourished or cachexic which can lead to increased rates of mortality (Basile, 2019)
- Cachexia can result in reduced quality of life, overall survival, muscle mass and tolerance to treatment (NICE, 2018)
- Important to focus on high energy high protein diet, supplement drinks if tolerated and little and often approach. Consideration of enteral and parenteral nutrition when necessary















Treatment and management of pancreatic cancer & staging













Type 3C diabetes

- Can occur due to exocrine insufficiency due to disease of the pancreas e.g pancreatic cancer
- It is important to be aware that this can occur pre or post surgery/ diagnosis
- Important to have diabetes nurses involved and raise with team
- Diabetes advice and education should be provided for these patients
- Referred to diabetes dietitian if necessary











What is Pancreatic exocrine insufficiency

The pancreas has an essential role in the digestion, absorption, and metabolism of carbohydrates, fats, and proteins.

Pancreas produces >30 enzymes but main 3 enzymes

Lipase required to breakdown fats (specific enzymes have varied amounts of lipase, e.g 25,000, 10,000)

Protease required to breakdown protein

Amylase required to breakdown carbohydrates

Damage to the cells producing pancreatic enzymes leads to exocrine pancreatic insufficiency, which is a serious problem leading to malnutrition and complications

It is important to encourage patients that they can continue to follow a normal diet and do not need to restrict their fat intake











When should you start PERT

 Any patient who has been diagnosed with unresectable pancreatic cancer should be commenced on PERT (NICE, 2018)

- Patient who have had diagnosis of head of pancreas cancer
- Total pancreatectomy
- Pre and post surgery for head of pancreas cancer (Phillips et al 2021)











How to take PERT

- Take capsules whole with water or other cold drink- taking with hot food/drinks can denature enzymes
- Can consume with room temperature drink if on chemo regimen containing oxaliplatin
- If swallowing difficulties- enzymes can be opened and taken with non-acidic food e.g fruit puree, banana, jam etc
- Rinse mouth thoroughly if opening capsules
- Take immediately before and during meal or snack- can stagger throughout meal or take all before
- Ensure enough fluids as high strength PEI replacement
- Store in cool dry place out of sunlight
- Ensure to carry in case, DO NOT place in pocket as enzymes can denature and will not work effectively
- Advise on porcine content of enzymes











Foods which require more **PERT**

- Fried foods e.g. cooked in frying pan
- Fried meats
- **Puddings**
- Oily dressings
- Chocolate drinks unless low fat style
- Crisps or nuts
- **Takeaways**

Foods which do not need PERT

- Jelly
- Fresh or tinned fruit
- Sweets e.g wine gums, boiled sweets, mints
- Fizzy drinks
- Squash
- Tea and coffee with dash of milk
- Glucose















How to monitor Enzymes













Am I taking enough PERT?

Should no longer have smelly offensive fatty stools Bowels should return to normal Should not have pain when eating Might gain some weight

> As appetite improves remember to increase dose











Still have signs of malabsorption; have you considered?

Fat soluble vitamin screen Bile acid malabsorption Coeliac screen stool sample PPI













Question 3:

What would you <u>not</u> need creon with?

- Banana and toast with butter
- Tea with small dash of milk
- Fortisip compact protein
- 125g fruit yogurt with seeds













Pancreatic Enzymes:

Creon 10,000 (remember may need more capsules due to lower dose)

Creon 25,000 (highest strength enzymes)

Nutrizym 22,000 (may need to increase dose)

Pancrex v powder not licensed for over 2g via tube feed











Case study 1

83year old lady, new diagnosis of pancreatic cancer and type 3 diabetes BMI 21kg/m2

Poor appetite eating <1000kcal <30g protein including x1 fortisip compact protein daily

Some nausea and reflux

Blood sugars raised, on metformin and input from diabetes team Bowels normal, on creon 25,000 x3 with meals and x2 with snacks.

What do you prioritise in this case?

Diabetes or poor appetite?











Plan:

Has the patient been referred to diabetes team

Provide education on high energy/ protein diabetic diet

Continue with creon

Encourage little and often as able

Priority is eating and drinking due to ++ poor appetite

Advise on hyperglycaemia risk and raise with appropriate team

Consider increasing supplement drinks if patient can tolerate to build up oral intake

? Take as shot style but ensure that x1 creon is taken with each 40ml shot of supplement to aid absorption

Monitor bowels and signs of malabsorption on review due to increase in kcal and protein intake

Consider if on PPI and anti sickness tablets











Case study 2:

70year old male, newly diagnosed with pancreatic cancer

BMI 17kg/m2 struggling to put on weight. Has been taking supplement drinks but struggles with abdominal pain after eating and taking supplements.

Not on pancreatic enzymes

Yellow loose stools, fatty consistency and cramps/ bloating

Fatigued and not keen to eat













Plan:

Commence on pancreatic enzymes and arrange script Starting dose 2-3 with meals and 1-2 with snacks

Provide education on enzymes

Continue with supplement drinks but ensure taking enzymes with each drink approx. 2 enzymes with each supplement

High energy/ high protein diet advice as tolerated

Little and often with regular snacks as able











Case study 3:

New dietetic referral for an 85year old male, pancreatic cancer diagnosis On creon since diagnosis but having issues with swallowing creon 25,000.

BMI 18kg/m2, has lost weight over last few weeks approx. 3kg. Reported continues to take creon but struggling with them at present

Ongoing nausea, pain on eating, wind and pale stools Reported taking x3 creon with meals and x2 with snacks

Keen to gain weight and reduce symptoms above













Plan

Consider opening creon capsules with all food, ensure and advise to rinse mouth after taking capsules

Take with non-acidic product yogurt to ensure enzymes do not denature prior to getting to stomach

Consider use of supplements commence fortisip compact protein x2 daily and ensure to take x2 creon with each supplement drink

Monitor bowels and weight











Some top tips

Ensure to work closely with MDT including CNS

Plan and review in timely manner

Review creon administration at each review

Ask if unsure and can reach out of BCH

Make sure patients are taking enzymes with supplement drinks

Spend time with patients to provide good education PERT can be overwhelming

Always ask about bowels











References

- PENG a pocket guide to clinical nutrition. 19.17 aims of pancreatic cancer and diet management, cancer diet management
- Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer(CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol. 2016 Nov;1(3):226-237. doi: 10.1016/S2468-1253(16)30106-6. Epub 2016 Oct 12. PMID: 28404095; PMCID: PMC5495015.
- Ghodeif AO, Azer SA. Pancreatic Insufficiency. [Updated 2023 Jan 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555926/
- Nice.org.uk. (2018). Overview | Pancreatic cancer in adults: diagnosis and management | Guidance | NICE. [online] Available at: https://www.nice.org.uk/guidance/ng85.
- Pancreatic Cancer UK. (n.d.). What do my test results mean? [online] Available at: https://www.pancreaticcancer.org.uk/information/how-is-pancreatic-cancerdiagnosed/what-do-my-test-results-mean/.











References

- Baker Rogers J, Syed K, Minteer JF. Cachexia. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470208/
- Basile, D., Parnofiello, A., Vitale, M., Cortiula, F., Gerratana, L., Fanotto, V., Lisanti, C., Pelizzari, G., Ongaro, E., Bartoletti, M., Garattini, S., Andreotti, V., Bacco, A., Iacono, D., Bonotto, M., Casagrande, M., Ermacora, P., Puglisi, F., Pella, N., Fasola, G., Aprile, G. and Cardellino, G., 2019. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 10(2), pp.368-377.
- Phillips ME, Hopper AD, Leeds JS, Roberts KJ, McGeeney L, Duggan SN, Kumar R. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021 Jun;8(1):e000643. doi: 10.1136/bmjgast-2021-000643. PMID: 34140324; PMCID: PMC8212181RICOCHET Study Group on behalf of the West Midlands Research Collaborative. Pancreatic enzyme replacement therapy in patients with pancreatic cancer: A national prospective study. Pancreatology. 2021 May 25:S1424-3903(21)00469-5. doi: 10.1016/j.pan.2021.05.299. Epub ahead of print. PMID: 34053863. Olson SH, Xu Y, Herzog K, Saldia A, DeFilippis EM, Li P, Allen PJ, O'Reilly EM, Kurtz RC. Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. Pancreas. 2016 Aug;45(7):986-91. doi:
 - 10.1097/MPA.0000000000000590. PMID: 26692445: PMCID: PMC4912937.









